Pressure-Treated Yeast Fiber Compounds May Benefit IPF Patients
An inhalable therapeutic is being developed using pressure-treated yeast beta-glucan for people with COVID-19 as well as other severe lung diseases, including idiopathic pulmonary fibrosis (IPF) is being developed by Ceapro Inc. in collaboration with Drs. Kjetil Ask and Todd Hoare.
Related News
News Listing
Two Faculty of Health Sciences cancer researchers awarded Canada Research Chairs
Dept. Biochem, Dept. Surgery, Feature, Research
7 days ago
Elena Verdu appointed director of Farncombe Family Digestive Health Research Institute
Faculty & Staff, Research
7 days ago